Crary Shelley E, Mack Joana M
Division of Pediatric Hematology-Oncology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USA.
Res Pract Thromb Haemost. 2024 Apr 3;8(3):102402. doi: 10.1016/j.rpth.2024.102402. eCollection 2024 Mar.
A State of the Art lecture titled "Anticoagulation and Vascular Anomalies" was presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in 2023. Vascular anomalies have been classified by the International Society for the Study of Vascular Anomalies into vascular tumors and vascular malformations. Although some vascular tumors, such as tufted angioma and kaposiform hemangioendothelioma, and other vascular malformations can present with coagulation aberrancies, these are not generally managed with anticoagulation. A subclassification of vascular malformations includes slow-flow vascular malformations. It is this subgroup specifically that has a high risk of venous thromboembolism (VTE) and morbidity associated with coagulopathy that may be present. In these select cases, anticoagulation may be indicated to reduce the risk of VTE, treat VTE, or manage localized thrombosis in the malformation that causes significant pain and reduced quality of life. There are established risk factors for VTE in these patients that will be reviewed. Finally, we summarize relevant new data on this topic presented during the 2023 ISTH Congress.
一场题为“抗凝与血管异常”的前沿讲座于2023年在国际血栓与止血学会（ISTH）大会上发表。血管异常已被国际血管异常研究学会分为血管肿瘤和血管畸形。尽管一些血管肿瘤，如丛状血管瘤和卡波西样血管内皮瘤，以及其他血管畸形可出现凝血异常，但这些情况一般不用抗凝治疗。血管畸形的一个亚分类包括低流速血管畸形。正是这一亚组特别具有静脉血栓栓塞（VTE）的高风险以及可能存在的与凝血病相关的发病率。在这些特定病例中，可能需要抗凝以降低VTE风险、治疗VTE或处理导致严重疼痛和生活质量下降的畸形内局部血栓形成。将对这些患者发生VTE的既定风险因素进行回顾。最后，我们总结在2023年ISTH大会期间提出的关于该主题的相关新数据。
